Your browser doesn't support javascript.
loading
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Ennishi, Daisuke; Takata, Katsuyoshi; Béguelin, Wendy; Duns, Gerben; Mottok, Anja; Farinha, Pedro; Bashashati, Ali; Saberi, Saeed; Boyle, Merrill; Meissner, Barbara; Ben-Neriah, Susana; Woolcock, Bruce W; Telenius, Adèle; Lai, Daniel; Teater, Matt; Kridel, Robert; Savage, Kerry J; Sehn, Laurie H; Morin, Ryan D; Marra, Marco A; Shah, Sohrab P; Connors, Joseph M; Gascoyne, Randy D; Scott, David W; Melnick, Ari M; Steidl, Christian.
Afiliación
  • Ennishi D; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Takata K; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Béguelin W; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Duns G; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Mottok A; Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
  • Farinha P; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Bashashati A; Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Saberi S; Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Boyle M; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Meissner B; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Ben-Neriah S; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Woolcock BW; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Telenius A; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Lai D; Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Teater M; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Kridel R; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Savage KJ; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Sehn LH; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Morin RD; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Marra MA; Genome Science Centre, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Shah SP; Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Connors JM; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Gascoyne RD; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Scott DW; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
  • Melnick AM; Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
  • Steidl C; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada. CSteidl@bccancer.bc.ca.
Cancer Discov ; 9(4): 546-563, 2019 04.
Article en En | MEDLINE | ID: mdl-30705065
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulación Neoplásica de la Expresión Génica / Proteína Potenciadora del Homólogo Zeste 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Regulación Neoplásica de la Expresión Génica / Proteína Potenciadora del Homólogo Zeste 2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article País de afiliación: Canadá